ProPhase Labs, Inc. Secured Debt, Current
ProPhase Labs, Inc. (PRPH) had Secured Debt, Current of $1.49 million as of 2016-12-31, per its 10-Q/A filed 2018-08-20.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:SecuredDebtCurrent · last filed 2018-08-20
- 2016-12-31: Secured Debt, Current $1.49M.
- 2016-09-30: Secured Debt, Current $1.48M.
- 2016-06-30: Secured Debt, Current $1.48M.
| Period end | Secured Debt, Current |
|---|---|
| 2016-12-31 | $1.49M 10-Q/A · filed 2018-08-20 |
| 2016-09-30 | $1.48M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $1.48M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |